NZ574978A - Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies - Google Patents

Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Info

Publication number
NZ574978A
NZ574978A NZ574978A NZ57497807A NZ574978A NZ 574978 A NZ574978 A NZ 574978A NZ 574978 A NZ574978 A NZ 574978A NZ 57497807 A NZ57497807 A NZ 57497807A NZ 574978 A NZ574978 A NZ 574978A
Authority
NZ
New Zealand
Prior art keywords
multiple myeloma
antibodies
methods
combination therapies
treating multiple
Prior art date
Application number
NZ574978A
Other languages
English (en)
Inventor
Daniel Afar
Kenneth C Anderson
Yu-Tzu Tai
Original Assignee
Dana Farber Cancer Inst Inc
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ574978(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc, Abbott Biotherapeutics Corp filed Critical Dana Farber Cancer Inst Inc
Publication of NZ574978A publication Critical patent/NZ574978A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
NZ574978A 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies NZ574978A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
NZ574978A true NZ574978A (en) 2012-08-31

Family

ID=38831279

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ574978A NZ574978A (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Country Status (23)

Country Link
US (4) US8632772B2 (cg-RX-API-DMAC7.html)
EP (5) EP2641600A1 (cg-RX-API-DMAC7.html)
JP (1) JP5340935B2 (cg-RX-API-DMAC7.html)
CN (1) CN101686971B (cg-RX-API-DMAC7.html)
AU (1) AU2007281684C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716647A2 (cg-RX-API-DMAC7.html)
CA (1) CA2660356C (cg-RX-API-DMAC7.html)
CY (5) CY1116247T1 (cg-RX-API-DMAC7.html)
DK (2) DK2641601T3 (cg-RX-API-DMAC7.html)
ES (2) ES2535437T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20150449T1 (cg-RX-API-DMAC7.html)
HU (4) HUE029027T2 (cg-RX-API-DMAC7.html)
IL (2) IL196919A (cg-RX-API-DMAC7.html)
LT (4) LT2641601T (cg-RX-API-DMAC7.html)
LU (3) LU93276I2 (cg-RX-API-DMAC7.html)
MX (1) MX2009001441A (cg-RX-API-DMAC7.html)
NL (1) NL300840I2 (cg-RX-API-DMAC7.html)
NO (1) NO346835B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ574978A (cg-RX-API-DMAC7.html)
PL (2) PL2641601T3 (cg-RX-API-DMAC7.html)
PT (2) PT2068874E (cg-RX-API-DMAC7.html)
SI (2) SI2068874T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008019378A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019376A2 (en) 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
BRPI0716647A2 (pt) 2006-08-07 2017-05-16 Dana Farber Cancer Inst Inc processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1
EP2300034B1 (en) * 2008-06-02 2018-08-08 Dana-Farber Cancer Institute, Inc. Pharmaceutical composition for use in treating or preventing multiple myeloma or waldenstrom's macroglobulinemia
CA2727278A1 (en) * 2008-06-16 2010-01-21 Immunogen, Inc. Novel synergistic effects
AU2009308516B2 (en) * 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
ES2502541T3 (es) 2009-09-10 2014-10-03 Kyowa Hakko Kirin Co., Ltd. Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4)
JP2013512195A (ja) * 2009-11-24 2013-04-11 セルジーン コーポレイション ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
US10494433B2 (en) 2013-11-06 2019-12-03 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
CA2924268C (en) * 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
FI3182996T3 (fi) 2014-08-22 2023-03-28 Celgene Corp Menetelmiä multippelin myelooman hoitamiseksi immuunivastetta muuntavilla yhdisteillä yhdistelmässä vasta-aineiden kanssa
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR20170088984A (ko) 2014-12-04 2017-08-02 브리스톨-마이어스 스큅 컴퍼니 암 (골수종)을 치료하기 위한 항-cs1 항체와 항-pd1 항체의 조합
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
JP6754785B2 (ja) 2015-06-29 2020-09-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫治療投与レジメンおよびその組合せ
CN109395058A (zh) * 2016-03-13 2019-03-01 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
SG11201907923VA (en) 2017-03-29 2019-09-27 Agency Science Tech & Res Anti oligosaccharide antibody
AU2018372924A1 (en) * 2017-11-22 2020-04-23 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP2022553821A (ja) 2019-11-05 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー Ｍ－タンパク質アッセイおよびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
DE69633668T2 (de) 1995-05-25 2006-03-09 Shimon Slavin Allogene zelltherapie für krebs infolge allogener stammzellen transplantation
CA2752140A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
AU2005302083A1 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
BRPI0716647A2 (pt) 2006-08-07 2017-05-16 Dana Farber Cancer Inst Inc processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
WO2008019376A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma

Also Published As

Publication number Publication date
HUS1600043I1 (hu) 2016-12-28
EP3115049A1 (en) 2017-01-11
HRP20150449T1 (xx) 2015-06-05
EP2641601A1 (en) 2013-09-25
CA2660356A1 (en) 2008-02-14
WO2008019378A1 (en) 2008-02-14
EP2942057A1 (en) 2015-11-11
CY1116247T1 (el) 2017-02-08
HUS1600044I1 (hu) 2016-12-28
LU93277I2 (fr) 2016-12-27
NO346835B1 (no) 2023-01-23
PL2641601T3 (pl) 2017-01-31
IL196919A0 (en) 2009-11-18
EP2641601B1 (en) 2016-07-06
JP5340935B2 (ja) 2013-11-13
US8632772B2 (en) 2014-01-21
LTC2068874I2 (lt) 2018-11-12
ES2535437T3 (es) 2015-05-11
CN101686971A (zh) 2010-03-31
US20080152646A1 (en) 2008-06-26
HRP20161284T1 (hr) 2016-12-16
MX2009001441A (es) 2009-07-06
US20170342150A1 (en) 2017-11-30
CN101686971B (zh) 2013-09-11
NL300840I2 (cg-RX-API-DMAC7.html) 2017-01-03
SI2068874T1 (sl) 2015-06-30
AU2007281684A1 (en) 2008-02-14
CY2016036I2 (el) 2017-07-12
BRPI0716647A2 (pt) 2017-05-16
IL196919A (en) 2016-03-31
LU93276I2 (fr) 2016-12-27
PT2641601T (pt) 2016-10-14
HUS1600045I1 (hu) 2016-12-28
CY1117992T1 (el) 2017-05-17
HUE029027T2 (en) 2017-01-30
CY2016037I1 (el) 2017-07-12
CY2016036I1 (el) 2017-07-12
AU2007281684C1 (en) 2013-12-19
PT2068874E (pt) 2015-05-21
EP2068874B1 (en) 2015-01-28
LTPA2016031I1 (lt) 2016-11-10
IL243933A0 (en) 2016-04-21
CY2016038I1 (el) 2017-07-12
NO20090968L (no) 2009-04-30
LU93275I2 (fr) 2016-12-27
EP2641601B8 (en) 2016-09-21
SI2641601T1 (sl) 2016-11-30
LTPA2016030I1 (lt) 2016-11-10
LTPA2016029I1 (lt) 2016-11-10
DK2068874T3 (da) 2015-04-27
PL2068874T3 (pl) 2015-06-30
EP2068874A1 (en) 2009-06-17
DK2641601T3 (en) 2016-08-22
JP2010500371A (ja) 2010-01-07
HK1129853A1 (en) 2009-12-11
US20140322201A1 (en) 2014-10-30
EP2641600A1 (en) 2013-09-25
ES2589302T3 (es) 2016-11-11
LT2641601T (lt) 2016-10-10
CA2660356C (en) 2016-04-05
AU2007281684B2 (en) 2013-05-16
US20160137735A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
NZ574978A (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
NZ597676A (en) Crystalline anti-hTNFalpha antibodies
IL261019A (en) Antibodies to 6 -il and their use
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
TW200720289A (en) Antibodies against CCR5 and uses thereof
EP1684805B8 (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
NZ599497A (en) Humanized antibodies to amyloid beta
NZ598594A (en) Combinatorial therapy involving alpha5beta1 antagonists
JP2013542191A5 (cg-RX-API-DMAC7.html)
NZ714516A (en) Human antibodies to clostridium difficile toxins
NZ598063A (en) Gram-positive bacteria specific binding compounds
MX2010005099A (es) Usos de anticuerpos anti-cd40.
NZ594285A (en) USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
NZ617298A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
NZ603607A (en) Cgrp antibodies
NZ592215A (en) c-MET ANTIBODIES
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
NZ602020A (en) Anti-cd40 antibodies
JP2015514110A5 (cg-RX-API-DMAC7.html)
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ712765A (en) Antibodies that bind csf1r

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: DANA-FARBER CANCER INSTITUTE, US

Free format text: OLD OWNER(S): PDL BIOPHARMA, INC.; DANA-FARBER CANCER INSTITUTE

Owner name: FACET BITOECH CORPORATION, US

Free format text: OLD OWNER(S): PDL BIOPHARMA, INC.; DANA-FARBER CANCER INSTITUTE

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 AUG 2014 BY DAVIES COLLISON CAVE

Effective date: 20130104

ASS Change of ownership

Owner name: DANA-FARBER CANCER INSTITUTE, US

Effective date: 20130829

Owner name: ABBVIE BIOTHERAPEUTICS INC., US

Effective date: 20130829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 AUG 2017 BY THOMSON REUTERS

Effective date: 20140619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2018 BY THOMSON REUTERS

Effective date: 20170720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2019 BY THOMSON REUTERS

Effective date: 20180721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2020 BY THOMSON REUTERS

Effective date: 20190725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2021 BY THOMSON REUTERS

Effective date: 20200721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2022 BY THOMSON REUTERS

Effective date: 20210702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2023 BY THOMSON REUTERS

Effective date: 20220704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2024 BY THOMSON REUTERS

Effective date: 20230703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2025 BY THOMSON REUTERS

Effective date: 20240702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 AUG 2026 BY THOMSON REUTERS

Effective date: 20250701